Endoscopy 2012; 44(02): 114-121
DOI: 10.1055/s-0031-1291459
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms

S-J. Cho
1   Center for Gastric Cancer, National Cancer Center, Korea
,
I. J. Choi
1   Center for Gastric Cancer, National Cancer Center, Korea
,
C. G. Kim
1   Center for Gastric Cancer, National Cancer Center, Korea
,
J. Y. Lee
1   Center for Gastric Cancer, National Cancer Center, Korea
,
B.-H. Nam
2   Center for Clinical Trials, National Cancer Center, Korea
,
M. H. Kwak
3   Cardiology, Center for Clinical Specialty, National Cancer Center, Korea
,
H. J. Kim
3   Cardiology, Center for Clinical Specialty, National Cancer Center, Korea
,
K. W. Ryu
1   Center for Gastric Cancer, National Cancer Center, Korea
,
J. H. Lee
1   Center for Gastric Cancer, National Cancer Center, Korea
,
Y.-W. Kim
1   Center for Gastric Cancer, National Cancer Center, Korea
› Institutsangaben
Weitere Informationen

Publikationsverlauf

submitted 09. Dezember 2010

accepted after revision 29. Juli 2011

Publikationsdatum:
23. Januar 2012 (online)

Background and study aim: The risk of bleeding after endoscopic submucosal dissection (ESD) in patients with early gastric neoplasms who do not discontinue aspirin for the procedure has not been established. We aimed to investigate whether post-ESD gastric bleeding is increased in patients who take aspirin.

Patients and methods: Patients who underwent ESD for early gastric neoplasms at the National Cancer Center Hospital, Korea, between November 2008 and January 2011 were enrolled. The risk of post-ESD bleeding was evaluated using Poisson regression analysis.

Results: We categorized 514 patients into three groups according to aspirin intake at the time of the procedure: patients who never used aspirin (n = 439), patients who interrupted aspirin use for 7 days or more (n = 56), and patients who continuously used aspirin (n = 19). Post-ESD bleeding occurred in 4.1 % (21 /514) overall, and was more frequent in continuous aspirin users (4 /19 [21.1 %]) than in those who never used aspirin (15 /439 [3.4 %]) (P = 0.006) and those with interrupted aspirin use (2 /56 [3.6 %]) (P = 0.033). Multivariate analysis showed that use of aspirin by itself was associated with post-ESD bleeding (relative risk [RR] 4.49; 95 % confidence interval [95 %CI] 1.09 – 18.38). The resumption of clopidogrel combined with aspirin use (RR 26.71, 95 %CI 7.09 – 100.53), and increased iatrogenic ulcer size (RR 1.52, 95 %CI 1.14 – 2.02), were significantly associated with post-ESD bleeding.

Conclusions: Continuous aspirin use increases the risk of bleeding after gastric ESD. Aspirin use should be stopped in patients with a low risk for thromboembolic disease to minimize bleeding complications.

 
  • References

  • 1 Makar GA, Ginsberg GG. Therapy insight: approaching endoscopy in anticoagulated patients. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 43-52
  • 2 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649
  • 3 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
  • 4 Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
  • 5 Ferrari E, Benhamou M, Cerboni P et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-459
  • 6 Anderson MA, Ben-Menachem T, Gan SI et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060-1070
  • 7 Veitch AM, Baglin TP, Gershlick AH et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57: 1322-1329
  • 8 Muehldorfer SM, Stolte M, Martus P et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut 2002; 50: 465-470
  • 9 Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15: 347-351
  • 10 Wexner SD, Garbus JE, Singh JJ. A prospective analysis of 13,580 colonoscopies. Reevaluation of credentialing guidelines. Surg Endosc 2001; 15: 251-261
  • 11 Nelson DB, McQuaid KR, Bond JH et al. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc 2002; 55: 307-314
  • 12 Ahmad NA, Kochman ML, Long WB et al. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002; 55: 390-396
  • 13 Eswaran SL, Sanders M, Bernadino KP et al. Success and complications of endoscopic removal of giant duodenal and ampullary polyps: a comparative series. Gastrointest Endosc 2006; 64: 925-932
  • 14 Cao Y, Liao C, Tan A et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009; 41: 751-757
  • 15 Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma – 2nd English Edition. Gastric Cancer 1998; 10-24
  • 16 Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906
  • 17 Bonow RO, Carabello BA, Chatterjee K et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52: 1-142
  • 18 Kushner FG, Hand M, Smith SC Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241
  • 19 King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295
  • 20 Toyoda K, Okada Y, Kobayashi S. Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study. Cerebrovasc Dis 2007; 24: 289-295
  • 21 Mosler P, Mergener K, Denzer U et al. Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy – a nation-wide survey in Germany. Z Gastroenterol 2004; 42: 1289-1293
  • 22 Fujishiro M, Oda I, Yamamoto Y et al. Multi-center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan. J Gastroenterol Hepatol 2009; 24: 214-218
  • 23 Lee SY, Tang SJ, Rockey DC et al. Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West. Gastrointest Endosc 2008; 67: 1076-1081
  • 24 Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104: 3085-3097
  • 25 Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40: 458-462
  • 26 Yousfi M, Gostout CJ, Baron TH et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99: 1785-1789
  • 27 Hui AJ, Wong RM, Ching JY et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44-48
  • 28 Okada K, Yamamoto Y, Kasuga A et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc 2011; 25: 98-107
  • 29 Goto O, Fujishiro M, Kodashima S et al. A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc 2010; 71: 241-248
  • 30 Takizawa K, Oda I, Gotoda T et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection – an analysis of risk factors. Endoscopy 2008; 40: 179-183
  • 31 Ono S, Fujishiro M, Niimi K et al. Technical feasibility of endoscopic submucosal dissection for early gastric cancer in patients taking anti-coagulants or anti-platelet agents. Dig Liver Dis 2009; 41: 725-728
  • 32 Tsuji Y, Ohata K, Ito T et al. Risk factors for bleeding after endoscopic submucosal dissection for gastric lesions. World J Gastroenterol 2010; 16: 2913-2917
  • 33 Wang AY, Emura F, Oda I et al. Endoscopic submucosal dissection with electrosurgical knives in a patient on aspirin therapy (with video). Gastrointest Endosc 2010; 72: 1066-1071
  • 34 Mauri L, Hsieh WH, Massaro JM et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029
  • 35 Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726-730
  • 36 Zuckerman MJ, Hirota WK, Adler DG et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc 2005; 61: 189-194
  • 37 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-1672
  • 38 Ye BD, Cheon JH, Choi KD et al. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther 2006; 24: 837-843
  • 39 Uedo N, Takeuchi Y, Yamada T et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol 2007; 102: 1610-1616
  • 40 Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103: 2890-2907
  • 41 Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41: 929-942